Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
75 hedge funds and large institutions have $230M invested in Global Blood Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 14 reducing their positions, and 13 closing their positions.
176,150% more call options, than puts
Call options by funds: $17.6M | Put options by funds: $10K
157% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 14
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
10% more funds holding
Funds holding: 68 → 75 (+7)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
51% less capital invested
Capital invested by funds: $470M → $230M (-$240M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.89M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$3.7M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$3.55M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
+$2.49M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$14.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.3M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.6M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$7.07M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.66M |
GBT Hedge Fund Activity: Q1 2016 in Review
75 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2016, worth a combined $230M — down 51% from $470M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new GBT positions and 13 closed out — a net gain of 7 holders — while 36 added to existing stakes and 14 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.89M. The largest seller was RA Capital Management, exiting entirely with an estimated $14.8M sold.
- 75 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2016, up from 68 in Q4 2015.
- Funds reported $230M of Global Blood Therapeutics, Inc. stock for Q1 2016, down 51% quarter-over-quarter.
- 20 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2016 and 13 closed out, a net change of +7 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2016 was Vanguard Group, an estimated $5.89M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2016 was RA Capital Management, an estimated $14.8M sold.
Based on aggregated 13F filings for Q1 2016.